David L. Grinblatt

685 total citations
58 papers, 461 citations indexed

About

David L. Grinblatt is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, David L. Grinblatt has authored 58 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 28 papers in Genetics and 21 papers in Pathology and Forensic Medicine. Recurrent topics in David L. Grinblatt's work include Acute Myeloid Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (20 papers) and Chronic Lymphocytic Leukemia Research (19 papers). David L. Grinblatt is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (20 papers) and Chronic Lymphocytic Leukemia Research (19 papers). David L. Grinblatt collaborates with scholars based in United States, Philippines and United Kingdom. David L. Grinblatt's co-authors include Arlene S. Swern, Kristen Sullivan, Rami S. Komrokji, Leo I. Gordon, Richard Meagher, Lynne Kaminer, Martin S. Tallman, Jeff P. Sharman, Andrew M. Evens and Jane N. Winter and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David L. Grinblatt

55 papers receiving 454 citations

Peers

Countries citing papers authored by David L. Grinblatt

Since Specialization

Citations

This map shows the geographic impact of David L. Grinblatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Grinblatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Grinblatt more than expected).

Fields of papers citing papers by David L. Grinblatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Grinblatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Grinblatt. The network helps show where David L. Grinblatt may publish in the future.

Co-authorship network of co-authors of David L. Grinblatt

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Grinblatt. A scholar is included among the top collaborators of David L. Grinblatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Grinblatt. David L. Grinblatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study 2025 ·Cancer ·Marlise R. Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy, Krzysztof Mrózek, C. D. Bloomfield, Spero R. Cataland, Noreen Fulton, Jonathan E. Kolitz, Betsy LaPlant, (unknown), Bayard L. Powell, Ravi Vij, Eunice S. Wang, David L. Grinblatt, Richard M. Stone, Geoffrey L. Uy, Richard A. Larson, Wendy Stock	2
2	Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), David L. Grinblatt	0
3	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Anthony R. Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, (unknown), Kristen Sullivan, E. Dawn Flick, Jeff P. Sharman	24
4	Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States 2017 ·BMC Cancer ·Chadi Nabhan, Anthony R. Mato, Christopher R. Flowers, David L. Grinblatt, Nicole Lamanna, Mark A. Weiss, Matthew S. Davids, Arlene S. Swern, (unknown), Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Jeff P. Sharman	8
5	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry. 2015 ·Journal of Clinical Oncology ·Anthony R. Mato, Christopher R. Flowers, Charles M. Farber, Mark A. Weiss, Thomas J. Kipps, Mark Kozloff, Chadi Nabhan, Ian W. Flinn, David L. Grinblatt, Nicole Lamanna, Kristen Sullivan, Pavel Kiselev, E. Dawn Flick, Kenneth A. Foon, Arlene S. Swern, Jeff P. Sharman	2
6	Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA^®registry 2014 ·Leukemia & lymphoma ·David L. Grinblatt, Mikkael A. Sekeres, Rami S. Komrokji, Arlene S. Swern, Kristen Sullivan, Mohit Narang	25
7	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia 2013 ·Supportive Care in Cancer ·Chris L. Pashos, Christopher R. Flowers, Neil E. Kay, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Susan Lerner, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, M. Kozloff, Arlene S. Swern, (unknown), Kristen Sullivan, Gale Harding, Zeba M. Khan	29
8	PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia 2012 ·Value in Health ·(unknown), Christopher R. Flowers, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Thomas J. Kipps, Susan Lerner, Neil E. Kay, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S. Swern, (unknown), (unknown), Kathleen A. Sullivan, Gale Harding, Michael J. Keating	1
9	Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL). 2012 ·Journal of Clinical Oncology ·Christopher R. Flowers, Chris L. Pashos, Mark A. Weiss, Nicole Lamanna, Charles M. Farber, Thomas J. Kipps, Susan Lerner, Neil E. Kay, Jeff P. Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S. Swern, Zeba M. Khan, (unknown), Kristen Sullivan, Michael J. Keating, Ren Yu	3
10	PSY72 VARIATION BY AGE IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS INITIATING TREATMENT FOR MYELODYSPLASTIC SYNDROMES 2011 ·Value in Health ·(unknown), David L. Grinblatt, Rami S. Komrokji, Mikkael A. Sekeres, Mohit Narang, Kathleen A. Sullivan, (unknown), (unknown)	1
11	Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas 2010 ·Leukemia & lymphoma ·Xavier Poiré, Justin Kline, David L. Grinblatt, Todd M. Zimmerman, (unknown), (unknown), Thomas F. Gajewski, Koen van Besien, Sonali M. Smith	11
12	Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan 2008 ·Cancer ·David L. Grinblatt, Daohai Yu, Vera Hárs, James W. Vardiman, Bayard L. Powell, Sreenivasa Nattam, Lewis R. Silverman, Carlos de Castro Lozano, Richard M. Stone, Clara D. Bloomfield, Richard A. Larson, (unknown)	5
13	Thalidomide has limited single‐agent activity in relapsed or refractory indolent non‐Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B 2008 ·British Journal of Haematology ·Sonali M. Smith, David L. Grinblatt, Jeffrey L. Johnson, Donna Niedzwiecki, David A. Rizzieri, Nancy L. Bartlett, Bruce D. Cheson, (unknown)	23
14	Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? 2006 ·Bone Marrow Transplantation ·Jayesh Mehta, Leo I. Gordon, Martin S. Tallman, Jane N. Winter, Andrew M. Evens, Olga Frankfurt, Stephanie Williams, David L. Grinblatt, Lynne Kaminer, Richard Meagher, Seema Singhal	45
15	Immunoglobulin for Concurrent Guillain-Barré and Immune Thrombocytopenic Purpura 2005 ·Pediatric Neurology ·Lawrence A. Zeidman, (unknown), David L. Grinblatt, Krisztina Harsanyi	5
16	Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study 2005 ·Cancer Chemotherapy and Pharmacology ·Cheri E. Klein, Helen Kastrissios, Antonius A. Miller, Donna Hollis, Daohai Yu, Gary L. Rosner, David L. Grinblatt, Richard A. Larson, Mark J. Ratain	23
17	Autologous and allogeneic transplantation for aggressive NHL 2002 ·Cytotherapy ·Sonali M. Smith, David L. Grinblatt, Koen van Besien	11
18	Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer 2000 ·Cytotherapy ·(unknown), Frank H. Valone, Todd M. Zimmerman, David L. Grinblatt, Peter Van Vlasselaer, (unknown), S F Williams	1
19	Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. 1995 ·PubMed ·(unknown), (unknown), (unknown), David L. Grinblatt, M. Campion, BW Cooper, H Gunn, S Manfreda, (unknown)	25
20	Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck 1994 ·Investigational New Drugs ·Merrill S. Kies, David L. Grinblatt, Melissa Runge‐Morris, Richard R. Blough, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact